Manfred Jung

Prof. Manfred Jung

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2016 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
LMLudovica Morera
Ludovica Morera
MLMichael Lübbert
Michael Lübbert
MJManfred Jung
Manfred Jung
The term epigenetics is defined as heritable changes in gene expression that are not due to alterations of the DNA sequence. In the last years, it has become more and more evident that dysregulated epigenetic regulatory processes have a central role in cancer onset and progression. In contrast to DNA mutations, epigenetic modifications are reversible and, hence, suitable for pharmacological interventions. Reversible histone methylation is an important process within epigenetic regulation, and the investigation of its role in cancer has led to the identification of lysine methyltransferases and demethylases as promising targets for new anticancer drugs. In this review, we describe those enzymes and their inhibitors that have already reached the first stages of clinical trials in cancer therapy, namely the histone methyltransferases DOT1L and EZH2 as well as the demethylase LSD1.

9 November 2010 in Clinical Epigenetics
Verified
Journal Article
Open access
JWJulia M. Wagner
Julia M. Wagner
BHBjörn Hackanson
Björn Hackanson
MLMichael Lübbert
Michael Lübbert
MJManfred Jung
Manfred Jung
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open ...

8 February 2005 in PLOS Biology
Verified
Journal Article
Open access
PDF file
SPSara Pagans
Sara Pagans
APAngelika Pedal
Angelika Pedal
BNBrian J North
Brian J North
KKKatrin Kaehlcke
Katrin Kaehlcke
BMBrett L Marshall
Brett L Marshall
MOMelanie Ott
Melanie Ott
The human immunodeficiency virus (HIV) Tat protein is acetylated by the transcriptional coactivator p300, a necessary step in Tat-mediated transactivation. We report here that Tat is deacetylated by human sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent class III protein deacetylase in vitro and in vivo. Tat and SIRT1 coimmunoprecipitate and synergistically activate the HIV promoter. Conversely, knockdown of SIRT1 via small interfering RNAs or treatment with a novel small molecule inhibitor of the SIRT1 deacetylase activity inhibit Tat-mediated transactivation of the HIV long terminal repeat. Tat transactivation is defective in SIRT1-null mouse embryonic fibroblasts and can be rescued by expression of SIRT1. These results support a model in which cycles of Tat acetylation and deacetylation regulate HIV transcription. SIRT1 recycles Tat to its unacetylated form and acts as a transcriptional coactivator during Tat transactivation.

12 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TRTobias Rumpf
Tobias Rumpf
MSMatthias Schiedel
Matthias Schiedel
BMBerin Karaman Mayack
Berin Karaman Mayack
CRClaudia Roessler
Claudia Roessler
BNBrian J. North
Brian J. North
MJManfred Jung
Manfred Jung
Sirtuins are a highly conserved class of NAD+-dependent lysine deacylases. The human isotype Sirt2 has been implicated in the pathogenesis of cancer, inflammation and neurodegeneration, which makes the modulation of Sirt2 activity a promising strategy for pharmaceutical intervention. A rational basis for the development of optimized Sirt2 inhibitors is lacking so far. Here we present high-resolution structures of human Sirt2 in complex with highly selective drug-like inhibitors that show a unique inhibitory mechanism. Potency and the unprecedented Sirt2 selectivity are based on a ligand-induced structural rearrangement of the active site unveiling a yet-unexploited binding pocket. Application of the most potent Sirtuin-rearranging ligand, termed SirReal2, leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1, consistent with Sirt2 inhibition in vivo. Our structural insights into this unique mechanism of selective sirtuin inhibition provide the basis for further inhibitor development and selective tools for sirtuin biology.

1 July 2015 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
ACAlokta Chakrabarti
Alokta Chakrabarti
IOIna Oehme
Ina Oehme
OWOlaf Witt
Olaf Witt
GOGuilherme Oliveira
Guilherme Oliveira
Wolfgang SipplWolfgang Sippl
Wolfgang Sippl
MJManfred Jung
Manfred Jung
Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.

17 April 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMatthias Schiedel
Matthias Schiedel
DHDaniel Herp
Daniel Herp
SHSören Hammelmann
Sören Hammelmann
SSSören Swyter
Sören Swyter
ALAttila Lehotzky
Attila Lehotzky
MJManfred Jung
Manfred Jung